Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150)
- 주제(키워드) Intravenous busulfan , Melphalan , Multiple myeloma , Autologous transplantation
- 주제(기타) Hematology; Immunology; Transplantation
- 설명문(일반) [Jung, Sung-Hoon; Lee, Je-Jung] Chonnam Natl Univ, Hwasun Hosp, Dept Hematol Oncol, 322 Seoyangro, Hwasun 519763, Jeollanamdo, South Korea; [Kim, Jin Seok] Yonsei Univ, Coll Med, Severance Hosp, Dept Internal Med, Seoul, South Korea; [Min, Chang-Ki] Catholic Univ Korea, Seoul St Marys Hosp, Dept Internal Med, Seoul, South Korea; [Kim, Kihyun] Samsung Med Ctr, Div Hematol Oncol, Dept Med, Seoul, South Korea; [Choi, Yunsuk] Ulsan Univ Hosp, Dept Internal Med, Ulsan, South Korea; [Eom, Hyeon-Seok] Natl Canc Ctr, Dept Hematol Oncol, Goyang Si, South Korea; [Joo, Young Don] Inje Univ, Busan Paik Hosp, Dept Hematol Oncol, Busan, South Korea; [Kim, Sung-Hyun] Dong A Med Ctr, Dept Hematol Oncol, Busan, South Korea; [Kwak, Jae-Yong] Chonbuk Natl Univ, Sch Med, Dept Internal Med, Jeonju, South Korea; [Kang, Hye Jin] Korea Canc Ctr Hosp, Korea Inst Radiol & Med Sci, Dept Internal Med, Seoul, South Korea; [Lee, Jae Hoon] Gachon Univ, Gil Hosp, Dept Internal Med, Incheon, South Korea; [Lee, Ho Sup] Kosin Univ, Gospel Hosp, Dept Internal Med, Busan, South Korea; [Mun, Yeung-Chul] Ewha Womans Univ, Sch Med, Dept Internal Med, Seoul, South Korea; [Moon, Joon Ho; Sohn, Sang Kyun] Kyungpook Natl Univ Hosp, Dept Hematol Oncol, Daegu, South Korea; [Park, Seong Kyu] Soonchunhyang Univ, Bucheon Hosp, Dept Internal Med, Bucheon, South Korea; [Park, Yong] Korea Univ, Coll Med, Dept Internal Med, Div Hematol Oncol, Seoul, South Korea; [Shin, Ho-Jin] Pusan Natl Univ Hosp, Dept Internal Med, Busan, South Korea; [Yoon, Sung-Soo] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
- 등재 SCIE, SCOPUS
- 발행기관 ELSEVIER SCIENCE INC
- 발행년도 2018
- URI http://www.dcollection.net/handler/ewha/000000151589
- 본문언어 영어
- Published As http://dx.doi.org/10.1016/j.bbmt.2018.01.004
초록/요약
This prospective study evaluated the efficacy and toxicity of intravenous busulfan and melphalan as a conditioning regimen for autologous stern cell transplantation (ASCT) in patients with multiple myeloma (MM). A total of 99 patients with MM, enrolled between January 2013 and March 2016, received intravenous busulfan (9.6 mg/kg) and melphalan (140 mg/m(2)) before ASCT. The median time to transplant was 6.2 months, and 90 (90.9%) patients underwent ASCT within 12 months of the diagnosis. The overall response rate after ASCT was 94.0%, including 43.5% with a stringent complete response/complete response, 27.3% with very good partial response, and 23.2% with partial response. The most common severe nonhematologic toxicity (grade 3 to 4) was infection (26.3%) and stomatitis (15.2%). Three (3.2%) patients developed veno-occlusive disease. No treatment-related mortality was observed. After a median follow-up of 26.1 months, the median progression free survival was 27.2 months (range, 13.0 to 41.4 months) and median overall survival was not reached. In conclusion, a conditioning regimen of intravenous busulfan and melphalan was effective and tolerable. ClinicalTrials.gov. number: NCT01923935 (C) 2018 American Society for Blood and Marrow Transplantation.
more